{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:12:43Z","timestamp":1792699963573,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02364358"],"award-info":[{"award-number":["RF-2016-02364358"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2021-12373889"],"award-info":[{"award-number":["RF-2021-12373889"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MAD-2022-12375656"],"award-info":[{"award-number":["PNRR-MAD-2022-12375656"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common liver disease worldwide. The risk of developing MAFLD varies among individuals, due to a combination of environmental inherited and acquired genetic factors. Genome-wide association and next-generation sequencing studies are leading to the discovery of the common and rare genetic determinants of MAFLD. Thanks to the great advances in genomic technologies and bioinformatics analysis, genetic and epigenetic factors involved in the disease can be used to develop genetic risk scores specific for liver-related complications, which can improve risk stratification. Genetic and epigenetic factors lead to the identification of specific sub-phenotypes of MAFLD, and predict the individual response to a pharmacological therapy. Moreover, the variant transcripts and protein themselves represent new therapeutic targets. This review will discuss the current status of research into genetic as well as epigenetic modifiers of MAFLD development and progression.<\/jats:p>","DOI":"10.1007\/s12072-024-10667-5","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T01:01:51Z","timestamp":1714006911000},"page":"848-860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["The contribution of genetics and epigenetics to MAFLD susceptibility"],"prefix":"10.1007","volume":"18","author":[{"given":"Vittoria","family":"Moretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-0345","authenticated-orcid":false,"given":"Luca","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"issue":"1","key":"10667_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73(1):202\u2013209. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039","journal-title":"J Hepatol"},{"issue":"6 Part 2","key":"10667_CR2","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S1262-3636(08)74597-X","volume":"34","author":"L Serfaty","year":"2008","unstructured":"Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab 2008;34(6 Part 2):634\u2013637. https:\/\/doi.org\/10.1016\/S1262-3636(08)74597-X","journal-title":"Diabetes Metab"},{"key":"10667_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003","journal-title":"J Hepatol"},{"issue":"7","key":"10667_CR4","doi-asserted-by":"publisher","first-page":"e00207","DOI":"10.1097\/hc9.0000000000000207","volume":"7","author":"F Ilyas","year":"2023","unstructured":"Ilyas F, et al. Increasing nonalcoholic fatty liver disease\u2013related mortality rates in the United States from 1999 to 2022. Hepatol Commun 2023;7(7):e00207. https:\/\/doi.org\/10.1097\/hc9.0000000000000207","journal-title":"Hepatol Commun"},{"issue":"2","key":"10667_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","volume":"10","author":"E Kaya","year":"2022","unstructured":"Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol 2022;10(2):329\u2013338. https:\/\/doi.org\/10.14218\/JCTH.2021.00178","journal-title":"J Clin Transl Hepatol"},{"issue":"5","key":"10667_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-277X.2005.00634.x","volume":"18","author":"R Rocha","year":"2005","unstructured":"Rocha R, Cotrim HP, Carvalho FM, Siqueira AC, Braga H, Freitas LA. Body mass index and waist circumference in non-alcoholic fatty liver disease. J Hum Nutr Diet 2005;18(5):365\u2013370. https:\/\/doi.org\/10.1111\/j.1365-277X.2005.00634.x","journal-title":"J Hum Nutr Diet"},{"issue":"10","key":"10667_CR7","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.3390\/ijerph18105227","volume":"18","author":"O Juanola","year":"2021","unstructured":"Juanola O, Mart\u00ednez-L\u00f3pez S, Franc\u00e9s R, G\u00f3mez-Hurtado I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int J Environ Res Public Health 2021;18(10):5227. https:\/\/doi.org\/10.3390\/ijerph18105227","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"10667_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/liv.15205","volume":"42","author":"L Valenti","year":"2022","unstructured":"Valenti L, Ronzoni L. Genetics: a new clinical tool for the hepatologist. Liver Int 2022;42(4):724\u2013726. https:\/\/doi.org\/10.1111\/liv.15205","journal-title":"Liver Int"},{"issue":"6","key":"10667_CR9","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","volume":"72","author":"E Tr\u00e9po","year":"2020","unstructured":"Tr\u00e9po E, Valenti L. Update on NAFLD genetics: from new variants to the clinic. J Hepatol 2020;72(6):1196\u20131209. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.020","journal-title":"J Hepatol"},{"issue":"4","key":"10667_CR10","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/liv.15185","volume":"42","author":"S Pelusi","year":"2022","unstructured":"Pelusi S, et al. Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: a case series. Liver Int 2022;42(4):864\u2013870. https:\/\/doi.org\/10.1111\/liv.15185","journal-title":"Liver Int"},{"key":"10667_CR11","doi-asserted-by":"crossref","unstructured":"Zheng M et al. Advancing diagnosis and management of liver disease in adults through exome sequencing. EBioMedicine 2023;95:104747. [Online]. Available: https:\/\/pan.ukbb.broadinstitute.org\/","DOI":"10.1016\/j.ebiom.2023.104747"},{"issue":"7","key":"10667_CR12","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1172\/JCI93465","volume":"127","author":"C Caussy","year":"2017","unstructured":"Caussy C, et al. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest 2017;127(7):2697\u20132704. https:\/\/doi.org\/10.1172\/JCI93465","journal-title":"J Clin Invest"},{"issue":"7","key":"10667_CR13","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1053\/j.gastro.2015.08.011","volume":"149","author":"R Loomba","year":"2015","unstructured":"Loomba R, et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 2015;149(7):1784\u20131793. https:\/\/doi.org\/10.1053\/j.gastro.2015.08.011","journal-title":"Gastroenterology"},{"issue":"5","key":"10667_CR14","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1053\/j.gastro.2009.01.050","volume":"136","author":"JB Schwimmer","year":"2009","unstructured":"Schwimmer JB, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009;136(5):1585\u20131592. https:\/\/doi.org\/10.1053\/j.gastro.2009.01.050","journal-title":"Gastroenterology"},{"issue":"4","key":"10667_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/liv.13956","volume":"39","author":"MT Long","year":"2019","unstructured":"Long MT, et al. Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring. Liver Int 2019;39(4):740\u2013747. https:\/\/doi.org\/10.1111\/liv.13956","journal-title":"Liver Int"},{"issue":"4","key":"10667_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/joim.12719","volume":"283","author":"P Dongiovanni","year":"2018","unstructured":"Dongiovanni P, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med 2018;283(4):356\u2013370. https:\/\/doi.org\/10.1111\/joim.12719","journal-title":"J Intern Med"},{"issue":"3","key":"10667_CR17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/hep.22726","volume":"49","author":"R Guerrero","year":"2009","unstructured":"Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009;49(3):791\u2013801. https:\/\/doi.org\/10.1002\/hep.22726","journal-title":"Hepatology"},{"key":"10667_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431\/suppinfo","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2015. https:\/\/doi.org\/10.1002\/hep.28431\/suppinfo","journal-title":"Hepatology"},{"issue":"10","key":"10667_CR19","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/liv.15322","volume":"42","author":"MJ Kubiliun","year":"2022","unstructured":"Kubiliun MJ, Cohen JC, Hobbs HH, Kozlitina J. Contribution of a genetic risk score to ethnic differences in fatty liver disease. Liver Int 2022;42(10):2227\u20132236. https:\/\/doi.org\/10.1111\/liv.15322","journal-title":"Liver Int"},{"key":"10667_CR20","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1111\/liv.15364","volume":"42","author":"S Romeo","year":"2022","unstructured":"Romeo S, Valenti L. African genetic ancestry and protection against fatty liver disease. Liver Int 2022;42:2122\u20132123","journal-title":"Liver Int"},{"key":"10667_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018;68:268\u2013279","journal-title":"J Hepatol"},{"issue":"12","key":"10667_CR22","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40(12):1461\u20131465. https:\/\/doi.org\/10.1038\/ng.257","journal-title":"Nat Genet"},{"issue":"4","key":"10667_CR23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina J, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014;46(4):352\u2013356. https:\/\/doi.org\/10.1038\/ng.2901","journal-title":"Nat Genet"},{"issue":"3","key":"10667_CR24","doi-asserted-by":"publisher","first-page":"e1001324","DOI":"10.1371\/journal.pgen.1001324","volume":"7","author":"EK Speliotes","year":"2011","unstructured":"Speliotes EK, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7(3):e1001324. https:\/\/doi.org\/10.1371\/journal.pgen.1001324","journal-title":"PLoS Genet"},{"issue":"5","key":"10667_CR25","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","volume":"150","author":"RM Mancina","year":"2016","unstructured":"Mancina RM, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent. Gastroenterology 2016;150(5):1219\u20131230.e6. https:\/\/doi.org\/10.1053\/j.gastro.2016.01.032","journal-title":"Gastroenterology"},{"issue":"1","key":"10667_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/hep.31229","volume":"72","author":"S Sookoian","year":"2020","unstructured":"Sookoian S, Pirola CJ, Valenti L, Davidson NO. Genetic pathways in nonalcoholic fatty liver disease: insights from systems biology. Hepatology 2020;72(1):330\u2013346. https:\/\/doi.org\/10.1002\/hep.31229","journal-title":"Hepatology"},{"issue":"41","key":"10667_CR27","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.3748\/wjg.v19.i41.6969","volume":"19","author":"P Dongiovanni","year":"2013","unstructured":"Dongiovanni P, et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013;19(41):6969\u20136978. https:\/\/doi.org\/10.3748\/wjg.v19.i41.6969","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10667_CR28","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cgh.2019.08.011","volume":"18","author":"S Grimaudo","year":"2020","unstructured":"Grimaudo S, et al. Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2020;18(4):935\u2013944.e3. https:\/\/doi.org\/10.1016\/j.cgh.2019.08.011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10667_CR29","doi-asserted-by":"publisher","first-page":"e1008955","DOI":"10.1371\/JOURNAL.PGEN.1008955","volume":"16","author":"BT Li","year":"2020","unstructured":"Li BT, et al. Disruption of the ERLIN\u2013TM6SF2\u2013APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease. PLoS Genet 2020;16(8):e1008955. https:\/\/doi.org\/10.1371\/JOURNAL.PGEN.1008955","journal-title":"PLoS Genet"},{"issue":"1","key":"10667_CR30","doi-asserted-by":"publisher","first-page":"11585","DOI":"10.1038\/s41598-019-47737-w","volume":"9","author":"S Prill","year":"2019","unstructured":"Prill S, et al. The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Sci Rep 2019;9(1):11585. https:\/\/doi.org\/10.1038\/s41598-019-47737-w","journal-title":"Sci Rep"},{"issue":"20","key":"10667_CR31","doi-asserted-by":"publisher","first-page":"10659","DOI":"10.1074\/jbc.M116.719955","volume":"291","author":"E Smagris","year":"2016","unstructured":"Smagris E, Gilyard S, BasuRay S, Cohen JC, Hobbs HH. Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J Biol Chem 2016;291(20):10659\u201310676. https:\/\/doi.org\/10.1074\/jbc.M116.719955","journal-title":"J Biol Chem"},{"key":"10667_CR32","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1038\/ncomms5309","volume":"5","author":"YL Liu","year":"2014","unstructured":"Liu YL, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014;5:4309. https:\/\/doi.org\/10.1038\/ncomms5309","journal-title":"Nat Commun"},{"issue":"1","key":"10667_CR33","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1038\/s41598-019-39998-2","volume":"9","author":"S Pelusi","year":"2019","unstructured":"Pelusi S, et al. Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease. Sci Rep 2019;9(1):3682. https:\/\/doi.org\/10.1038\/s41598-019-39998-2","journal-title":"Sci Rep"},{"issue":"12","key":"10667_CR34","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ng.3417","volume":"47","author":"S Buch","year":"2015","unstructured":"Buch S, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 2015;47(12):1443\u20131448. https:\/\/doi.org\/10.1038\/ng.3417","journal-title":"Nat Genet"},{"key":"10667_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01497-6","author":"Y Chen","year":"2023","unstructured":"Chen Y, et al. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat Genet 2023. https:\/\/doi.org\/10.1038\/s41588-023-01497-6","journal-title":"Nat Genet"},{"issue":"11","key":"10667_CR36","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41588-022-01199-5","volume":"54","author":"G Sveinbjornsson","year":"2022","unstructured":"Sveinbjornsson G, et al. Multiomics study of nonalcoholic fatty liver disease. Nat Genet 2022;54(11):652\u20131663","journal-title":"Nat Genet"},{"issue":"1","key":"10667_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s42255-021-00518-0","volume":"4","author":"RM Mancina","year":"2022","unstructured":"Mancina RM, et al. PSD3 downregulation confers protection against fatty liver disease. Nat Metab 2022;4(1):60\u201375. https:\/\/doi.org\/10.1038\/s42255-021-00518-0","journal-title":"Nat Metab"},{"issue":"4","key":"10667_CR38","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","volume":"74","author":"C Bianco","year":"2021","unstructured":"Bianco C, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol 2021;74(4):775\u2013782. https:\/\/doi.org\/10.1016\/j.jhep.2020.11.024","journal-title":"J Hepatol"},{"key":"10667_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.coph.2021.08.014","volume":"61","author":"C Bianco","year":"2021","unstructured":"Bianco C, Tavaglione F, Romeo S, Valenti L. Genetic risk scores and personalization of care in fatty liver disease. Curr Opin Pharmacol 2021;61:6\u201311. https:\/\/doi.org\/10.1016\/j.coph.2021.08.014","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"10667_CR40","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.cgh.2021.05.056","volume":"20","author":"A De Vincentis","year":"2022","unstructured":"De Vincentis A, et al. A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores. Clin Gastroenterol Hepatol 2022;20(3):658\u2013673. https:\/\/doi.org\/10.1016\/j.cgh.2021.05.056","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10667_CR41","doi-asserted-by":"publisher","first-page":"100066","DOI":"10.1016\/j.xgen.2021.100066","volume":"1","author":"ME Haas","year":"2021","unstructured":"Haas ME, et al. Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genomics 2021;1(3):100066. https:\/\/doi.org\/10.1016\/j.xgen.2021.100066","journal-title":"Cell Genomics"},{"key":"10667_CR42","unstructured":"Burnett JR, Hooper AJ, Hegele RA. APOB-related familial hypobetalipoproteinemia. GeneReviews\u00ae [Internet] 2021;1993\u20132023"},{"issue":"8","key":"10667_CR43","doi-asserted-by":"publisher","first-page":"100764","DOI":"10.1016\/j.jhepr.2023.100764","volume":"5","author":"JI Grove","year":"2023","unstructured":"Grove JI, et al. Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease. JHEP Rep 2023;5(8):100764. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100764","journal-title":"JHEP Rep"},{"issue":"6","key":"10667_CR44","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1194\/jlr.P090449","volume":"60","author":"P Dongiovanni","year":"2019","unstructured":"Dongiovanni P, et al. PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. J Lipid Res 2019;60(6):1144\u20131153. https:\/\/doi.org\/10.1194\/jlr.P090449","journal-title":"J Lipid Res"},{"issue":"7762","key":"10667_CR45","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41586-019-1310-4","volume":"570","author":"GL Wojcik","year":"2019","unstructured":"Wojcik GL, et al. Genetic analyses of diverse populations improves discovery for complex traits. Nature 2019;570(7762):514\u2013518. https:\/\/doi.org\/10.1038\/s41586-019-1310-4","journal-title":"Nature"},{"key":"10667_CR46","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","volume":"152","author":"Z Chen","year":"2020","unstructured":"Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med 2020;152:116\u2013141. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.02.025","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"10667_CR47","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1053\/j.gastro.2009.11.013","volume":"138","author":"L Valenti","year":"2010","unstructured":"Valenti L, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010;138(3):905\u2013912. https:\/\/doi.org\/10.1053\/j.gastro.2009.11.013","journal-title":"Gastroenterology"},{"key":"10667_CR48","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.12659\/MSM.896494","volume":"22","author":"S Milic","year":"2016","unstructured":"Milic S, et al. The role of iron and iron overload in chronic liver disease. Med Sci Monit 2016;22:2144\u20132151. https:\/\/doi.org\/10.12659\/MSM.896494","journal-title":"Med Sci Monit"},{"issue":"3","key":"10667_CR49","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2021.03.014","volume":"75","author":"E Corradini","year":"2021","unstructured":"Corradini E, et al. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. J Hepatol 2021;75(3):506\u2013513. https:\/\/doi.org\/10.1016\/j.jhep.2021.03.014","journal-title":"J Hepatol"},{"issue":"6","key":"10667_CR50","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41588-022-01078-z","volume":"54","author":"M Vujkovic","year":"2022","unstructured":"Vujkovic M, et al. A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nat Genet 2022;54(6):761\u2013771. https:\/\/doi.org\/10.1038\/s41588-022-01078-z","journal-title":"Nat Genet"},{"issue":"8","key":"10667_CR51","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1210\/jc.2017-00056","volume":"102","author":"S Petta","year":"2017","unstructured":"Petta S, et al. Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2017;102(8):2660\u20132669. https:\/\/doi.org\/10.1210\/jc.2017-00056","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10667_CR52","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jhep.2018.10.021","volume":"70","author":"M Metwally","year":"2019","unstructured":"Metwally M, et al. A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3\u2032UTR. J Hepatol 2019;70(3):494\u2013500. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.021","journal-title":"J Hepatol"},{"key":"10667_CR53","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/hep.29395\/suppinfo","volume":"66","author":"S Petta","year":"2017","unstructured":"Petta S, et al. Interferon lambda 4 rs368234815 TT>dG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology 2017;66:1885\u20131893. https:\/\/doi.org\/10.1002\/hep.29395\/suppinfo","journal-title":"Hepatology"},{"issue":"10","key":"10667_CR54","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1089\/jir.2018.0175","volume":"39","author":"M Eslam","year":"2019","unstructured":"Eslam M, Ahlenstiel G, George J. Interferon lambda and liver fibrosis. J Interf Cytokine Res 2019;39(10):627\u2013635","journal-title":"J Interf Cytokine Res"},{"issue":"7","key":"10667_CR55","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1507\/endocrj.EJ14-0052","volume":"64","author":"A Kitamoto","year":"2014","unstructured":"Kitamoto A, et al. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr J 2014;64(7):683\u2013689","journal-title":"Endocr J"},{"issue":"2","key":"10667_CR56","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1136\/gut.2009.190801","volume":"59","author":"P Dongiovanni","year":"2010","unstructured":"Dongiovanni P, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010;59(2):267\u2013273","journal-title":"Gut"},{"issue":"12","key":"10667_CR57","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/nejmoa1712191","volume":"378","author":"NS Abul-Husn","year":"2018","unstructured":"Abul-Husn NS, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 2018;378(12):1096\u20131106. https:\/\/doi.org\/10.1056\/nejmoa1712191","journal-title":"N Engl J Med"},{"issue":"3","key":"10667_CR58","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jhep.2022.03.031","volume":"77","author":"GA Baselli","year":"2022","unstructured":"Baselli GA, et al. Rare ATG7 genetic variants predispose patients to severe fatty liver disease. J Hepatol 2022;77(3):596\u2013606. https:\/\/doi.org\/10.1016\/j.jhep.2022.03.031","journal-title":"J Hepatol"},{"issue":"11","key":"10667_CR59","doi-asserted-by":"publisher","first-page":"e7926","DOI":"10.1371\/journal.pone.0007926","volume":"4","author":"RT Calado","year":"2009","unstructured":"Calado RT, et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS ONE 2009;4(11):e7926. https:\/\/doi.org\/10.1371\/journal.pone.0007926","journal-title":"PLoS ONE"},{"issue":"6","key":"10667_CR60","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/ng.3855","volume":"49","author":"S Stender","year":"2017","unstructured":"Stender S, Kozlitina J, Nordestgaard BG, Tybj\u00e6rg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 2017;49(6):842\u2013847. https:\/\/doi.org\/10.1038\/ng.3855","journal-title":"Nat Genet"},{"issue":"5","key":"10667_CR61","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/liv.15562","volume":"43","author":"F Tavaglione","year":"2023","unstructured":"Tavaglione F, Jamialahmadi O, Valenti L, Romeo S. Fatty liver disease genetic risk variants and interference on sex hormones. Liver Int 2023;43(5):958\u2013961. https:\/\/doi.org\/10.1111\/liv.15562","journal-title":"Liver Int"},{"issue":"3","key":"10667_CR62","doi-asserted-by":"publisher","first-page":"382","DOI":"10.5604\/16652681.1235481","volume":"16","author":"V Jaruvongvanich","year":"2017","unstructured":"Jaruvongvanich V, Sanguankeo A, Riangwiwat T, Upala S. Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Hepatol 2017;16(3):382\u2013394. https:\/\/doi.org\/10.5604\/16652681.1235481","journal-title":"Ann Hepatol"},{"issue":"1","key":"10667_CR63","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1210\/clinem\/dgab658","volume":"107","author":"C Falzarano","year":"2022","unstructured":"Falzarano C, et al. Nonalcoholic fatty liver disease in women and girls with polycystic ovary syndrome. J Clin Endocrinol Metab 2022;107(1):258\u2013272. https:\/\/doi.org\/10.1210\/clinem\/dgab658","journal-title":"J Clin Endocrinol Metab"},{"key":"10667_CR64","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1038\/s41591-023-02553-8","volume":"29","author":"A Cherubini","year":"2023","unstructured":"Cherubini A, et al. Interaction between estrogen receptor-\u03b1 and PNPLA3 p. I148M variant drives fatty liver disease susceptibility in women. Nat Med 2023;29:2643\u20132655. https:\/\/doi.org\/10.1038\/s41591-023-02553-8","journal-title":"Nat Med"},{"key":"10667_CR65","doi-asserted-by":"publisher","first-page":"294278","DOI":"10.1155\/2015\/294278","volume":"2015","author":"M Shen","year":"2015","unstructured":"Shen M, Shi H. Sex hormones and their receptors regulate liver energy homeostasis. Int J Endocrinol 2015;2015:294278. https:\/\/doi.org\/10.1155\/2015\/294278","journal-title":"Int J Endocrinol"},{"key":"10667_CR66","doi-asserted-by":"publisher","first-page":"538","DOI":"10.17632\/ktx7jp8sch.1","volume":"574","author":"SF Brunner","year":"2019","unstructured":"Brunner SF, et al. Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature 2019;574:538\u2013542. https:\/\/doi.org\/10.17632\/ktx7jp8sch.1","journal-title":"Nature"},{"issue":"5","key":"10667_CR67","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","volume":"149","author":"J Zucman-Rossi","year":"2015","unstructured":"Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015;149(5):1226\u20131239.e4. https:\/\/doi.org\/10.1053\/j.gastro.2015.05.061","journal-title":"Gastroenterology"},{"issue":"12","key":"10667_CR68","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1111\/liv.15103","volume":"41","author":"L Valenti","year":"2021","unstructured":"Valenti L, Romeo S, Pajvani U. A genetic hypothesis for burnt-out steatohepatitis. Liver Int 2021;41(12):2816\u20132818. https:\/\/doi.org\/10.1111\/liv.15103","journal-title":"Liver Int"},{"issue":"7881","key":"10667_CR69","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41586-021-03974-6","volume":"598","author":"SWK Ng","year":"2021","unstructured":"Ng SWK, et al. Convergent somatic mutations in metabolism genes in chronic liver disease. Nature 2021;598(7881):473\u2013478. https:\/\/doi.org\/10.1038\/s41586-021-03974-6","journal-title":"Nature"},{"key":"10667_CR70","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.acr.2020.10.002","volume":"149","author":"T Garcia-Lezana","year":"2021","unstructured":"Garcia-Lezana T, Lopez-Canovas JL, Villanueva A. Signaling pathways in hepatocellular carcinoma. Adv Cancer Res 2021;149:63\u2013101. https:\/\/doi.org\/10.1016\/bs.acr.2020.10.002","journal-title":"Adv Cancer Res"},{"issue":"4","key":"10667_CR71","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1053\/j.gastro.2016.11.042","volume":"152","author":"JC Nault","year":"2017","unstructured":"Nault JC, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology 2017;152(4):880\u2013894.e6. https:\/\/doi.org\/10.1053\/j.gastro.2016.11.042","journal-title":"Gastroenterology"},{"issue":"3","key":"10667_CR72","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3390\/ijms17030383","volume":"17","author":"B Donati","year":"2016","unstructured":"Donati B, Valenti L. Telomeres, NAFLD and chronic liver disease. Int J Mol Sci 2016;17(3):383. https:\/\/doi.org\/10.3390\/ijms17030383","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10667_CR73","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2641","volume":"15","author":"PAJ Muller","year":"2013","unstructured":"Muller PAJ, Vousden KH. P53 mutations in cancer. Nat Cell Biol 2013;15(1):2\u20138. https:\/\/doi.org\/10.1038\/ncb2641","journal-title":"Nat Cell Biol"},{"issue":"15","key":"10667_CR74","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1158\/1078-0432.CCR-16-3118","volume":"23","author":"S Rebouissou","year":"2017","unstructured":"Rebouissou S, et al. Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro. Clin Cancer Res 2017;23(15):4364\u20134375. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3118","journal-title":"Clin Cancer Res"},{"key":"10667_CR75","doi-asserted-by":"crossref","unstructured":"Satoh S, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. 2000. [Online]. Available: http:\/\/genetics.nature.com\/supplementary_info\/","DOI":"10.1038\/73448"},{"issue":"26","key":"10667_CR76","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/nejmoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014;371(26):2477\u20132487. https:\/\/doi.org\/10.1056\/nejmoa1409405","journal-title":"N Engl J Med"},{"key":"10667_CR77","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1101\/2022.01.17.22269409","volume":"616","author":"WJ Wong","year":"2023","unstructured":"Wong WJ, et al. Clonal hematopoiesis and risk of chronic liver disease. Nature 2023;616:747\u2013754. https:\/\/doi.org\/10.1101\/2022.01.17.22269409","journal-title":"Nature"},{"issue":"7939","key":"10667_CR78","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41586-022-05448-9","volume":"612","author":"MD Kessler","year":"2022","unstructured":"Kessler MD, et al. Common and rare variant associations with clonal haematopoiesis phenotypes. Nature 2022;612(7939):301\u2013309. https:\/\/doi.org\/10.1038\/s41586-022-05448-9","journal-title":"Nature"},{"key":"10667_CR79","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.pharmthera.2018.08.008","volume":"193","author":"A Ferrari","year":"2019","unstructured":"Ferrari A, et al. Epigenome modifiers and metabolic rewiring: new frontiers in therapeutics. Pharmacol Ther 2019;193:178\u2013193. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.08.008","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10667_CR80","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bbalip.2016.12.005","volume":"1862","author":"J Mwinyi","year":"2017","unstructured":"Mwinyi J, et al. NAFLD is associated with methylation shifts with relevance for the expression of genes involved in lipoprotein particle composition. Biochim Biophys Acta Mol Cell Biol Lipids 2017;1862(3):314\u2013323. https:\/\/doi.org\/10.1016\/j.bbalip.2016.12.005","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"9","key":"10667_CR81","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2012-302962","volume":"62","author":"CJ Pirola","year":"2013","unstructured":"Pirola CJ, et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2013;62(9):1356\u20131363. https:\/\/doi.org\/10.1136\/gutjnl-2012-302962","journal-title":"Gut"},{"issue":"8","key":"10667_CR82","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.3390\/nu6083303","volume":"6","author":"JH Lee","year":"2014","unstructured":"Lee JH, Friso S, Choi SW. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients 2014;6(8):3303\u20133325. https:\/\/doi.org\/10.3390\/nu6083303","journal-title":"Nutrients"},{"issue":"5","key":"10667_CR83","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1053\/j.gastro.2013.07.047","volume":"145","author":"SK Murphy","year":"2013","unstructured":"Murphy SK, et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology 2013;145(5):1076\u20131087. https:\/\/doi.org\/10.1053\/j.gastro.2013.07.047","journal-title":"Gastroenterology"},{"issue":"4","key":"10667_CR84","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/15592294.2017.1294305","volume":"12","author":"VD de Mello","year":"2017","unstructured":"de Mello VD, et al. Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action. Epigenetics 2017;12(4):287\u2013295. https:\/\/doi.org\/10.1080\/15592294.2017.1294305","journal-title":"Epigenetics"},{"key":"10667_CR85","unstructured":"Kitamoto T, et al. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. [Online]. Available: http:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/"},{"key":"10667_CR86","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28370\/suppinfo","author":"B Donati","year":"2015","unstructured":"Donati B, et al. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. Hepatology 2015. https:\/\/doi.org\/10.1002\/hep.28370\/suppinfo","journal-title":"Hepatology"},{"issue":"3","key":"10667_CR87","doi-asserted-by":"publisher","first-page":"E320","DOI":"10.1111\/hepr.12992","volume":"48","author":"K Hotta","year":"2018","unstructured":"Hotta K, et al. Identification of the genomic region under epigenetic regulation during non-alcoholic fatty liver disease progression. Hepatol Res 2018;48(3):E320\u2013E334. https:\/\/doi.org\/10.1111\/hepr.12992","journal-title":"Hepatol Res"},{"issue":"1","key":"10667_CR88","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13148-018-0525-9","volume":"10","author":"GS Gerhard","year":"2018","unstructured":"Gerhard GS, et al. Differentially methylated loci in NAFLD cirrhosis are associated with key signaling pathways. Clin Epigenet 2018;10(1):93. https:\/\/doi.org\/10.1186\/s13148-018-0525-9","journal-title":"Clin Epigenet"},{"issue":"9","key":"10667_CR89","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nrg1945","volume":"7","author":"RJ Klose","year":"2006","unstructured":"Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 2006;7(9):715\u2013727. https:\/\/doi.org\/10.1038\/nrg1945","journal-title":"Nat Rev Genet"},{"issue":"6116","key":"10667_CR90","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1126\/science.1233223","volume":"339","author":"AW Ferrante","year":"2013","unstructured":"Ferrante AW. Improving metabolism by throwing out all the JNK. Science 2013;339(6116):147\u2013148. https:\/\/doi.org\/10.1126\/science.1233223","journal-title":"Science"},{"issue":"12","key":"10667_CR91","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1172\/JCI41624","volume":"120","author":"J Bricambert","year":"2010","unstructured":"Bricambert J, Miranda J, Benhamed F, Girard J, Postic C, Dentin R. Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J Clin Invest 2010;120(12):4316\u20134331. https:\/\/doi.org\/10.1172\/JCI41624","journal-title":"J Clin Invest"},{"issue":"2","key":"10667_CR92","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/j.gastro.2013.10.059","volume":"146","author":"Y Li","year":"2014","unstructured":"Li Y, et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology 2014;146(2):539\u2013549. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.059","journal-title":"Gastroenterology"},{"issue":"12","key":"10667_CR93","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.3390\/ijms19123966","volume":"19","author":"P Dongiovanni","year":"2018","unstructured":"Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. MiRNA signature in NAFLD: a turning point for a non-invasive diagnosis. Int J Mol Sci 2018;19(12):3966. https:\/\/doi.org\/10.3390\/ijms19123966","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10667_CR94","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nrgastro.2013.87","volume":"10","author":"G Szabo","year":"2013","unstructured":"Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013;10(9):542\u2013552. https:\/\/doi.org\/10.1038\/nrgastro.2013.87","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"43","key":"10667_CR95","doi-asserted-by":"publisher","first-page":"15538","DOI":"10.1073\/pnas.1412759111","volume":"111","author":"S Horvath","year":"2014","unstructured":"Horvath S, et al. Obesity accelerates epigenetic aging of human liver. Proc Natl Acad Sci U S A 2014;111(43):15538\u201315543. https:\/\/doi.org\/10.1073\/pnas.1412759111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10667_CR96","doi-asserted-by":"publisher","first-page":"e23937","DOI":"10.1371\/journal.pone.0023937","volume":"6","author":"S Cermelli","year":"2011","unstructured":"Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 2011;6(8):e23937. https:\/\/doi.org\/10.1371\/journal.pone.0023937","journal-title":"PLoS ONE"},{"issue":"10","key":"10667_CR97","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/labinvest.2010.113","volume":"90","author":"IP Pogribny","year":"2010","unstructured":"Pogribny IP, et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Investig 2010;90(10):1437\u20131446. https:\/\/doi.org\/10.1038\/labinvest.2010.113","journal-title":"Lab Investig"},{"issue":"3","key":"10667_CR98","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/2211536607666180531093302","volume":"7","author":"K Jampoka","year":"2018","unstructured":"Jampoka K, Muangpaisarn P, Khongnomnan K, Treeprasertsuk S, Tangkijvanich P, Payungporn S. Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD). Microrna 2018;7(3):215\u2013222","journal-title":"Microrna"},{"issue":"2","key":"10667_CR99","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3390\/molecules24020230","volume":"24","author":"J Yu","year":"2019","unstructured":"Yu J, Peng J, Luan Z, Zheng F, Su W. MicroRNAs as a novel tool in the diagnosis of liver lipid dysregulation and fatty liver disease. Molecules 2019;24(2):230. https:\/\/doi.org\/10.3390\/molecules24020230","journal-title":"Molecules"},{"issue":"12","key":"10667_CR100","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.cellsig.2012.07.023","volume":"24","author":"Y He","year":"2012","unstructured":"He Y, Huang C, Zhang S, Sun X, Long X, Li J. The potential of microRNAs in liver fibrosis. Cell Signal 2012;24(12):2268\u20132272. https:\/\/doi.org\/10.1016\/j.cellsig.2012.07.023","journal-title":"Cell Signal"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10667-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10667-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10667-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:46:11Z","timestamp":1787226371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10667-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":100,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10667"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10667-5","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the funding information.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Vittoria Moretti, Stefano Romeo, and Luca Valenti have no conflicts of interest to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects.","order":2,"name":"Ethics","label":"Compliance with ethical requirements","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LV has received speaking fees from MSD, Gilead, AlfaSigma, and AbbVie, served as a consultant for Gilead, Pfizer, AstraZeneca, Novo Nordisk, Intercept, Diatech Pharmacogenetics, Ionis Pharmaceuticals, Boehringer Ingelheim, and Resalis Therapeutics, and received unrestricted research grants from Gilead.SR is consultant for Astra Zeneca, RIbocure Ab, Foresite Lab, Novartis, AMGEN, Sanofi, and Ultragenix. SR has received grants from Astra Zeneca for research in steatotic liver disease.","order":3,"name":"Ethics","label":"COI","group":{"name":"EthicsHeading","label":"Declarations"}}]}}